Rainer Ramses Erdtmann

WORK HISTORY

EDUCATION

ABOUT RAINER RAMSES ERDTMANN

Mr. Erdtmann has over 30 years of experience in the investment banking and the financial industries and 20 years of experience in biotech. He currently is President and COO of Biomea Fusion (NASDAQ: BMEA), a diabetes and obesity medicines company, which he cofounded in 2017. Prior to Biomea, Mr. Erdtmann was 7 years at Pharmacyclics, Inc.(NASDAQ: PCYC) and oversaw a broad range of departments while helping to grow the company from 47-634 employees. He began, leading the Finance Department and managing all Accounting, SEC Reporting, Audits and Investor Relations. He also built up and ran IT, HR, Legal, Facilities and Events for the company. Later, as the Executive Vice President of Corporate Affairs, he assumed additional responsibilities for Corporate Communications. Mr. Erdtmann actively participated in the final execution of key corporate milestones for Pharmacyclics, among them the Collaboration Agreement with J&J in 2011 (value $1.0 Billion) and the merger agreement with AbbVie in 2015 (value $21 Billion). Mr. Erdtmann currently serves on the board of Biomea Fusion (NASDAQ: BMEA), he also served on the boards of Summit Therapeutics (NASDAQ SMMT), a biopharmaceutical oncology company and served on the board of PolarityTE (NASDAQ PTE), a regenerative medicine company, where he was its Audit Committee Chair. Mr. Erdtmann began his career at Commerzbank in Germany, where he was an investment banker and portfolio manager for large institutional accounts. He earned the Diplom Kaufmann degree with honors in Finance and Banking from the Westfaelische Wilhelms Universitaet of Muenster, Germany, the equivalent to a US Master of Business Administration degree.